hypercholesterolemia

出典: meddic

高コレステロール血症

WordNet   license wordnet

「the presence of an abnormal amount of cholesterol in the cells and plasma of the blood; associated with the risk of atherosclerosis」
hypercholesteremia

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/05/16 08:04:38」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • The effects of high fat, low carbohydrate and low fat, high carbohydrate diets on tumor necrosis factor superfamily proteins and proinflammatory cytokines in C57BL/6 mice.
  • Sirjani M1, Taleban FA2, Hekmatdoost A3, Amiri Z4, Pellizzon M5, Hedayati M6, Bidad K7, Shokouhi Shoormasti R8, Pourpak Z9.Author information 1Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mahshidsrjn@gmail.com.2Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. talebanfa@yahoo.com.3Department of Clinical Nutrition and Dietetics, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a_hekmat2000@yahoo.com.4Department of Basic Sciences/Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Amiri_z@hotmail.com.5Research Diets, Inc., New Jersey, the United States of America. pourpakz@sina.tums.ac.ir.6Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hedayati47@gmail.com.7Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. katayoonb@yahoo.com.8Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. rshokouhi@farabi.tums.ac.ir.9Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. pourpakz@sina.tums.ac.ir.AbstractThere has been considerable inconsistency regarding the potential relationship between dyslipidemia and bone metabolism. The inflammatory stimulation through the receptor activator of the nuclear factor kappa-B ligand (RANKL)/ receptor activator of the nuclear factor kappa-B (RANK)/ osteoprotegerin (OPG) pathway could be the infrastructural mechanism for hypercholesterolemia-induced bone loss.In this study, we investigated the effect of dyslipidemia on RANKL and OPG alongside with pro-inflammatory cytokines. Thirty male C57Bl/6 mice (4 weeks old) were randomized to two purified diet groups (15 animals in each group), high fat, low carbohydrate diet (HFLCD) and its matched low fat, high carbohydrate diet (LFHCD). After 12 weeks of feeding in standard situations, the plasma concentration of lipid profile, interleukin (IL)1Beta,, IL-6, tumor necrosis factor-alpha (TNF-α) and RANKL, OPG, and RANKL: OPG ratio were measured.In the present study, although the body weight significantly increased during 12 weeks in HFLCD and LFHCD groups, there were no significant differences in food intake, food efficiency ratio and weight gain between the two groups. The LFHCD group had significantly higher median RANKL and RANKL/OPG ratio. There was no significant difference in plasma IL-1β, IL-6 and TNF-α concentration between LFHCD and HFLCD groups.These unexpected findings from LFHCD, that seem to be as a result of its higher carbohydrate proportion in comparison to HFLCD, implicate dietary carbohydrate rather than dietary fat as a more significant nutritional factor contributing to change in RANKL level and RANKL: OPG ratio. 
  • Iranian journal of allergy, asthma, and immunology.Iran J Allergy Asthma Immunol.2014 Aug;13(4):247-55.
  • There has been considerable inconsistency regarding the potential relationship between dyslipidemia and bone metabolism. The inflammatory stimulation through the receptor activator of the nuclear factor kappa-B ligand (RANKL)/ receptor activator of the nuclear factor kappa-B (RANK)/ osteoprotegerin
  • PMID 24659160
  • Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides.
  • Mukai H1, Ozaki D1, Cui Y1, Kuboyama T2, Yamato-Nagata H2, Onoe K1, Takahashi M1, Wada Y1, Imanishi T3, Kodama T3, Obika S4, Suzuki M1, Doi H1, Watanabe Y5.Author information 1Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies (CLST), 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.2Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies (CLST), 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.3Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan.4Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic address: obika@phs.osaka-u.ac.jp.5Division of Bio-function Dynamics Imaging, RIKEN Center for Life Science Technologies (CLST), 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. Electronic address: yywata@riken.jp.AbstractRecently, we demonstrated the utility of positron emission tomography (PET) imaging-based pharmacokinetic evaluation studies for preclinical experiments and microdose clinical trials, mainly focused on low molecular weight compounds. In order to investigate the pharmacokinetics of nucleic acid drugs and their drug delivery systems (DDSs) in vivo by using PET imaging, we developed a novel and efficient method for radiolabeling oligodeoxynucleotides with the positron-emitting radionuclide (18)F (stoichiometry-focused Huisgen-type (18)F labeling). By using this method, we succeeded in synthesizing a variety of (18)F-labeled oligodeoxynucleotides with not only phosphodiesters (PO) in natural forms, but also phosphorothioate (PS) and bridged nucleic acid (BNA) in artificial forms, and then performed PET studies and radioactive metabolite analyses of these (18)F-labeled oligodeoxynucleotides. The tissue-distribution and dynamic changes in radioactivity showed significantly different profiles between these antisense oligodeoxynucleotides. The radioactivity of (18)F-labeled PO-DNA and PO-BNA rapidly accumulated in the kidneys and liver and then moved to the renal medulla, ureter, bladder, and intestine. However, the radioactivity of (18)F-labeled PS-DNA and PS-BNA, possessing PS backbone structures, was retained in the blood for relatively long periods and then gradually accumulated in the liver and kidneys. The metabolite analysis showed that (18)F-labeled PO-DNA rapidly degraded by 5min and (18)F-labeled PO-BNA gradually degraded over time by 60min. Conversely, (18)F-labeled PS-DNA and PS-BNA were shown to be much more stable. To demonstrate the usefulness of the PET imaging technique for evaluating the improved targeting potential of the DDS, we designed and synthesized a cholesterol-modified oligodeoxynucleotide, that we developed as an antisense nucleic acid drug against proprotein convertase subtilisin/kexin type 9 (PCSK9) for hypercholesterolemia therapy, and evaluated its pharmacokinetics using PET imaging. As expected, the (18)F-labeled cholesterol-modified PS-BNA-type oligodeoxynucleotide showed much higher and more rapid accumulation in the delivery target organ, that is, the liver, which encourages us to develop this drug. These results suggest that dynamic PET studies using (18)F-incorporated oligodeoxynucleotide synthesized by stoichiometry-focused Huisgen-type labeling is useful for quantitative pharmacokinetic evaluation of nucleic acid drugs and their delivery systems.
  • Journal of controlled release : official journal of the Controlled Release Society.J Control Release.2014 Apr 28;180:92-9. doi: 10.1016/j.jconrel.2014.02.014. Epub 2014 Feb 22.
  • Recently, we demonstrated the utility of positron emission tomography (PET) imaging-based pharmacokinetic evaluation studies for preclinical experiments and microdose clinical trials, mainly focused on low molecular weight compounds. In order to investigate the pharmacokinetics of nucleic acid drugs
  • PMID 24566256
  • Distinct CD11b(+)-monocyte subsets accelerate endothelial cell recovery after acute and chronic endothelial cell damage.
  • Becher UM1, Möller L1, Tiyerili V1, Vasa Nicotera M1, Hauptmann F1, Zimmermann K2, Pfeifer A2, Nickenig G1, Wassmann S3, Werner N4.Author information 1Medizinische Klinik und Poliklinik II, Innere Medizin, Universitätsklinikum Bonn, Germany.2Institut für Pharmakologie und Toxikologie, Universitätsklinikum Bonn, Germany.3Kardiologische Abteilung, Innere Medizin, Isarklinik München, Germany.4Medizinische Klinik und Poliklinik II, Innere Medizin, Universitätsklinikum Bonn, Germany. Electronic address: nikos.werner@ukb.uni-bonn.de.AbstractBACKGROUND: Endothelial cell recovery requires replenishment of primary cells from the endothelial lineage. However, recent evidence suggests that cells of the innate immune system enhance endothelial regeneration.
  • International journal of cardiology.Int J Cardiol.2014 Apr 15;173(1):80-91. doi: 10.1016/j.ijcard.2014.02.004. Epub 2014 Feb 20.
  • BACKGROUND: Endothelial cell recovery requires replenishment of primary cells from the endothelial lineage. However, recent evidence suggests that cells of the innate immune system enhance endothelial regeneration.METHODS AND RESULTS: Focusing on mature CD11b(+)-monocytes, we analyzed the fate and t
  • PMID 24602320

和文文献

  • Diet-induced hypercholesterolemia imparts structure-function changes to erythrocyte chondroitin sulphate/dermatan sulphate
  • Kiran G.,Srikanth C. B.,Salimath P. V. [他]
  • The journal of biochemistry 158(3), 217-224, 2015-09
  • NAID 40020593521
  • 後天性止血異常を合併しlow density lipoproteinアフェレーシス施行時および子宮頸部生検時に止血困難な性器出血を来した家族性高コレステロール血症合併子宮頸癌の一例
  • 渡邉 憲和,高橋 俊文,永瀬 智
  • 山形大学紀要. 医学 : 山形医学 33(2), 97-102, 2015-08-15
  • NAID 110009957875
  • Effects of oral administration of tripeptides derived from type I collagen (collagen tripeptide) on atherosclerosis development in hypercholesterolemic rabbits(BREWING AND FOOD TECHNOLOGY)
  • Tang Lihua,Sakai Yasuo,Ueda Yoshimichi,Katsuda Shogo
  • Journal of bioscience and bioengineering 119(5), 558-563, 2015-05
  • … In order to evaluate the effects of Ctp on atherosclerosis development in vivo, here we used the Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbit model of familial hypercholesterolemia to determine the effects of oral administration of Ctp for three months. …
  • NAID 110009962611

関連リンク

Most cases of high cholesterol are not caused by a single inherited condition, but result from a combination of lifestyle choices and the effects of variations in many genes. Inherited forms of hypercholesterolemia resulting ...
Hypercholesterolemia Definition Hypercholesterolemia refers to levels of cholesterol in the blood that are higher than normal. Description Cholesterol circulates in the blood stream. It is an essential molecule for the human body.

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元脂質異常症」「高コレステロール血症」「hypercholesterolaemic」「hypercholesterolemic

脂質異常症」

  [★]

dyslipidemia
高脂血症 hyperlipidemia脂質代謝異常 lipoprotein disorders
高脂血症治療薬リポ蛋白

定義

  • 血清:Total-CHO≧220 mg/dl。LDL-C≧140 mg/dl。TG≧150 mg/dl。HDL-C<40 mg/dl

病型

  • 原発性
  • 家族性
  • 特発性
  • 二次性

分類

原発性高脂血症のWHO分類

型分類   増加するリポ蛋白 血清脂質の変動 コレステロール
(mg/dl)
トリグリセリド
(mg/dl)
正常   - - <220 <150
I型高脂血症 高カイロミクロン血症 hyperchylomicronemia カイロミクロン 中性脂肪著明増加 <260 >1000
IIa型高脂血症 高コレステロール血症 hypercholesterolemia LDL コレステロール増加 >220 >150
IIb型高脂血症 複合型高脂血症 combined hyperlipidemia LDL, VLDL コレステロール中性脂肪増加 >220 150-300
III型高脂血症 異常βリポ蛋白血症 dysbetalipoproteinemia IDL 電気泳動でbroad β 350-500 350-500
IV型高脂血症 高トリグリセリド血症 hypertriglyceridemia VLDL 中性脂肪増加 <240 200-1000
V型高脂血症 複合型高トリグリセリド血症 mixed hypertriglyceridemia カイロミクロン, VLDL 中性脂肪著明増加 <300 >1000

原発性高脂血症の型分類 (臨床検査法提要第32版 p.533)

  I型 II型 III型 IV型 V型
IIa型 IIb型
高カイロミクロン血症 高コレステロール血症 複合型高脂血症 異常βリポ蛋白血症 高トリグリセリド血症 複合型高トリグリセリド血症
増加リポ蛋白 CM ++        
VLDL      
IDL          
LDL        
血漿脂質 TC +++ ++ ++ /+
TG +++   ++ ++ ++ +++
TC/TG <0.2 >1.6 不定 0.6-1.6 <0.6
病因 LPL欠損
アポCII欠損
(外因性高脂血症)
LDL受容体異常 不明 アポE異常
(E2/E2など)
不明
(内因性高脂血症)
LPL欠損へテロ(一部)
(外因性高脂血症
and
(内因性混合型高脂血症)
臨床所見 発症時期 小児期 小児期~成人 成人 成人 小児期~成人
肝脾肥大
+++ +++
脾のみ
+++
腹痛    
膵炎      
網膜脂血症      
肥満      
角膜輪      
冠動脈疾患 まれ 最も高率 高率 中程度 比較的まれ
黄色腫 発疹状 黄色板状
結節状
腱黄色腫
手掌線
結節状
発疹状
  発疹状
耐糖能 正常 正常 正常 異常多い 異常多い
高尿酸血症 なし なし 少ない 多い 多い
遺伝 劣性遺伝 優性遺伝 劣性遺伝 優性遺伝 不明
頻度 まれ 多い
500人中
1人(ヘテロ)
100万人中
1人(ホモ)
多い
200人中
1人
少ない
1万人中
2-3人
最も多い まれ
血清静置試験 上層:乳濁 透明 わずかに混濁 混濁、
時にミルク状
混濁 上層:乳濁
下層:透明 下層:混濁
特徴     small dense LDL
の存在
broad β    
  • 頻度:IIa > IIb > IV
  • 遺伝(AR)I, III (AD)その他
  • 症状
  • 動脈硬化:IIa,IIb,III
  • 膵炎:TG多い:I,IV,V
  • TC優位に多いのがIIa, TG優位に多いのがIV
  • リポ蛋白のパターンは、IIa + IV = IIb で IIIはその中間(IDL)。I + IV = V

原発性高脂血症

  血清TG 血清TC
内分泌代謝疾患 甲状腺機能低下症   +++
クッシング症候群 + ++
先端性肥大症 +  
糖尿病 +++ +~++
痛風 +  
神経性食思不振症   ++
ウェルナー症候群   ++
肝疾患 閉塞性肝・胆道疾患   +++
肝癌   ++
腎疾患 ネフローゼ症候群 ++ +++
慢性腎不全 +++  
免疫異常 全身性エリテマトーデス +++  
骨髄腫 ++ +
薬剤など サイアザイド + +
β遮断薬 +  
シクロスポリン   +
経口避妊薬 +++  

リスク別脂質管理目標値 (http://jas.umin.ac.jp/pdf/guideline_summary.pdf)

  治療方針の原則 カテゴリー 脂質管理目標値(mg/dL)
リスク群 LDL-C以外の主要危険因子 LDL-C HDL-C TG
一次予防 まず生活習慣の改善を 行った後、薬物治療の 適応を考慮する I 低リスク群 0 <160 ≧40 <150
II 中リスク群 1~2 <140
III 高リスク群 3以上 <120
二次予防 生活習慣の改善とともに 薬物治療を考慮する 冠動脈疾患の既往 <100
  • LDL-C値以外の主要危険因子
  • 加齢(男性≧45歳、女性≧55歳)、高血圧、糖尿病(耐糖能異常を含む)、喫煙、冠動脈疾患の家族歴、低HDL-C血症(<40mg/dL)
  • 糖尿病、脳梗塞、閉塞性動脈硬化症の合併はカテゴリーIIIとする。




高コレステロール血症」

  [★]

hypercholesterolemia, hypercholesterolaemia
IIa型高脂血症 家族性高リポ蛋白血症IIa型高βリポタンパク血症? hyper β lipoproteinemia?
脂質異常症

分類

症状

  • 黄色腫、動脈硬化、角膜輪、欠席、高尿酸血症


hypercholesterolaemic」

  [★]

高コレステロール血症の

hypercholesteremiahypercholesterolaemiahypercholesterolemiahypercholesterolemic


hypercholesterolemic」

  [★]

  • 高コレステロール血症の
hypercholesteremiahypercholesterolaemiahypercholesterolaemichypercholesterolemia




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡